MeMed  

Nahum Het 5
Haifa,  4462747

Israel
https://www.me-med.com
  • Booth: 2641

MeMed, a leader in host response technologies, decodes the body’s complex signals into simple insights that improve people’s lives. By leveraging our expertise in host-response profiling and machine-learning algorithms, we are creating a portfolio of tests that address tough clinical dilemmas. MeMed Key® is a point-of-need, rapid measurement platform that delivers results in 15 minutes from serum. The MeMed BV® test accurately differentiates bacterial from viral infection, enabling improved patient management, including appropriate antibiotic use. BV which was clinically validated on thousands of patients, is CE-marked and 510(k) pending. The MeMed COVID-19 Severity™ test was developed to meet the urgent need during the ongoing pandemic of risk stratifying COVID-19 patients. Also run on Key in 15 minutes, this Disruptive Technology Award finalist is CE-marked and 510(k) pending. Visit us at booth #2641 to learn more.


 Videos

How the technology works

 Press Releases

  • MeMed COVID-19 Severity reads the immune-system in real time to accurately determine whether SARS-Cov-2 patients are likely to have a severe outcome

    HAIFA, Israel, August 5th, 2021 – MeMed, a leader in host response-based technologies, announces today that it has been named a finalist for the American Association of Clinical Chemistry’s (AACC) Disruptive Technology Award for the MeMed COVID-19 Severity™ test, which stratifies the risk that a patient with COVID-19 will experience severe outcomes. MeMed is one of three finalists that will present its technology at the 2021 AACC Annual Scientific Meeting in Atlanta, Georgia, during a session to be held on September 27th.

    Eran Eden, MeMed’s co-founder and CEO, said: “We are thrilled to be selected as a finalist for this esteemed award, which recognizes the importance of MeMed COVID-19 Severity™ as a tool which empowers physicians in managing the COVID-19 pandemic. Recently CE Marked in Europe, the test can provide valuable insights into which patients may worsen, enabling tailored treatments and helping to reduce burden on healthcare systems. We’re honored to be recognized by the AACC’s panel alongside the other finalists.”

    MeMed COVID-19 Severity™ is a pioneering host response technology that measures multiple proteins from a serum sample and applies machine learning to stratify the risk that a patient with COVID-19 will experience severe outcomes.

    The test runs in 15 minutes on the company’s point-of-need platform, MeMed Key®, and aims to help physicians identify who may benefit from escalated care and who can be safely discharged from hospital and to self-isolate at home. MeMed COVID-19 Severity™ has a CE Mark in Europe.

    About MeMed Our mission is to translate the immune system's complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society. For additional information on MeMed, please visit http://www.me-med.com.

  • FDA Clears First Technology to Distinguish between Bacterial and Viral Infections Using the Body’s Immune Response  The MeMed BV® Test and MeMed Key® Platform

    • MeMed BV is a first-of-its kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
       
    • MeMed Key is a pioneering platform that enables rapid and sensitive measurements of multiple proteins at the point-of-need
       
    • The MeMed technology suite enables better informed antibiotic treatment decisions, an essential tool in the fight against the global threat of resistant bacteria
       

    HAIFA, Israel, Boston, MA; September 20th, 2021 – MeMed, a leader in the emerging field of advanced host-response technologies, today announces that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for use of the MeMed BV® test on the point-of-need platform MeMed Key® to help healthcare providers distinguish between bacterial and viral infections. The technology has been cleared for both children and adults.

    Bacterial and viral infections are often clinically indistinguishable, leading to the prescription of antibiotics for the treatment of viral infections, for which they are ineffective. Antibiotic misuse drives the emergence of antimicrobial resistance (AMR), one of the biggest healthcare challenges of our time.
    The novelty of MeMed’s technology is that it decodes the body’s immune response to infection, the ‘host response’, rather than focusing on detecting the presence of a microbe. This allows robust diagnosis when the infection site is inaccessible or unknown, even when the pathogen is undetectable using conventional tests, or when the cause of infection are emerging new pathogens. It enables better informed antibiotic treatment decisions, an essential tool in the fight against resistant bacteria.

    “For those of us who care for acutely ill children, we have been waiting decades for accurate, rapid diagnostics to confidently guide the care of moderately ill children without a clear focus of infection or recognizable viral illness. This novel test offers promise to help differentiate those children with self-limited viral illness from those with possible bacterial infection, thereby supporting the judicious use of antibiotics,” said Rich Bachur, MD, Professor of Pediatrics and Emergency Medicine, Harvard Medical School, and Chief, Division of Emergency Medicine, Boston Children's Hospital.

    “It has been a decade long journey to reach this point from concept to impacting patient lives,” said Dr. Eran Eden, MeMed’s co-founder and CEO“This FDA clearance is a breakthrough moment in the field of advanced host-response and could not have been achieved without the dedication of the MeMed team, our clinical partners in the US and around the globe, and the support of the US Department of Defense and EU Commission.”

    Sergey Motov, MD, Professor of Emergency Medicine, Maimonides Medical Center, New York, said“Host-response technologies are a new frontier in the management of patients with infectious diseases, with great potential to improve patient outcomes. Every day, I see adults with a complicated medical history presenting to the emergency room with a suspected respiratory tract infection. A technology like MeMed BV can significantly aid in their management.”

    “We are now using MeMed BV in my department routinely to aid in determining whether a child with fever has a bacterial or viral infection. For example, we recently had a complicated case of a young child with fever but without a clear source. MeMed BV helped in early identification of a severe bacterial infection, that would otherwise be masked by viral PCR detection, lead to a change in the course of treatment, and made a big difference in the patient’s outcome,” said Dr Adi Klein, Director of the Pediatric Division, Hillel Yaffe Medical Center and Head of the Israeli Clinical Pediatric Society. “Introducing MeMed’s technology has had a significant impact on our medical practice, enabling us to be better stewards of antibiotics and improving patient outcomes.” 

    FDA clearance was based on a multi-center blinded clinical validation study enrolling over 1,000 children and adults and addresses goals laid out in the US National Action Plan for Combating Antibiotic Resistant Bacteria. The test provides highly accurate results with Area Under the Curve of 90% and 97% (primary and secondary endpoints). MeMed has established its US base in Boston and is ramping up commercial activities to ensure broad availability of its products across the US.

    About MeMed
    Our mission is to translate the immune system's complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society. To learn more about MeMed and our solutions, please visit http://www.me-med.com

    About MeMed BV®
    MeMed BV® is a first-of-its-kind immune-based protein signature test, developed and validated over the course of decade-long collaborations with leading academic and commercial partners. It provides physicians with an indispensable tool to help distinguish between bacterial and viral infections across multiple pathogens, even if the infection site is inaccessible or unknown. MeMed BV® measures and computationally integrates the levels of three immune system proteins: TRAIL, IP-10 and CRP. When run on the MeMed Key® platform, MeMed BV® provides a result within 15 minutes. MeMed BV® has been independently validated on thousands of patients and the results have been published in leading peer-reviewed journals (including PediatricsThe Lancet ID,  PLOS OneBMJ Peds and European Journal of Clinical Microbiology & Infectious Diseases). The MeMed BV® test has received a CE Mark in Europe and AMAR clearance from the Israeli Ministry of Health.

    About MeMed Key®
    MeMed Key® is a pioneering technology platform, enabling highly sensitive measurements of multiple proteins, within minutes, at the point of need. It opens the way to quantification of a vast array of human proteins in healthy and disease states, where and when it actually matters. The MeMed Key® development program has been partially funded by the US Department of Defense and the EU Commission. MeMed Key® has received a CE Mark in Europe and AMAR clearance from the Israeli Ministry of Health.

    MeMed Contacts:
    Adee Mor, VP Marketing, MeMed
    pr@me-med.com  
    Kfir Emmer, CFO, MeMed
    kfir.emmer@me-med.com

    Media relations contact:
    Consilium Strategic Communications MeMed@consilium-comms.com


 Products

  • MeMed BV® and MeMed Key®
    Run on the compact MeMed Key®, MeMed BV® is a host-immune response assay that can aid to distinguish between bacterial and viral infections delivering results in 15 minutes from serum. MeMed BV computationally integrates the levels of three host immune proteins into a simple score indicating the likelihood of a bacterial immune response/co-infection versus a viral immune response....
     

  • Imagine what your Antibiotic Stewardship Program would look like if you had a 15-minute serum test that could accurately differentiate between a bacterial and viral infection, and was validated in multiple multinational, double-blind clinical studies and real-world usage encompassing >20,000 patients?

    Run on the compact MeMed Key®, MeMed BV® is a host-immune response assay that can aid to distinguish between bacterial and viral infections. From a small serum sample, MeMed BV computationally integrates the levels of three host immune proteins into a simple score indicating the likelihood of a bacterial immune response or co-infection versus a viral immune response. Learn more at Booth #2641.


 Additional Info

Will your company display a new product or promote a new indication/enhanced feature(s) for an existing product in your booth?
Yes